Ranked by What Each Route Asks
The slowest route is the one with a clinician in it, and for this compound it is genuinely available rather than theoretical. That changes the ranking.
How to get sermorelin has a different answer from almost every other compound in this category, because the slow route with a prescriber in it actually exists here. Ranking the options by friction therefore means starting with the one most guides have to skip.
Where the order actually gets placed
Ascension Peptides, Sermorelin
US-based and third-party tested. Enter the code on the payment step and the vial halves before you confirm.
The published certificate for lot 38-01260229 assays this vial at 11.31 mg against a 10 mg label, and reports purity and quantity only, with no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Batch certificate published for this lot
- Shipping free over $250
- Same-day dispatch before 2pm CST
Everything here is research material for laboratory use, not for human consumption. Affiliate links, so we may earn a commission at no cost to you. Prices last checked September 6, 2026.
How to get sermorelin: the routes, slowest first
Friction is the useful axis because everything else follows from it. The routes that take longest are the ones with a person in them who can say no, and the routes that are instant are instant because nobody is assessing anything.
Ordering them by speed and ordering them by oversight produce exactly the same list in opposite directions. That is the whole decision.
Route one: a prescriber and a 503A compounding pharmacy
This is the highest-friction route and the one with the strongest footing.
Sermorelin was an approved US drug. Geref carried NDA 019863 for pituitary diagnostics, with submissions from 28 May 1991, and NDA 020443, approved on 26 September 1997 in 0.5 mg and 1 mg vials, both from EMD Serono. Both are marked Discontinued today, and FDA's product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons.
Under section 503A a compounding pharmacy may use a bulk drug substance that is a component of an FDA-approved drug product, even where no USP monograph exists. Sermorelin acetate was exactly that. It is also absent from FDA's Category 2 list of bulk substances identified as presenting significant safety risks, in every section, active and withdrawn, while ibutamoren mesylate appears there under both 503A and 503B and ipamorelin acetate, GHRP-2 and GHRP-6 appear there too.
What that route asks of you is a sequence of appointments. Find a prescriber willing to consider it, be assessed, have whatever laboratory work the prescriber wants, wait for a decision, and then wait for a pharmacy to compound and dispatch. Each step has an interval attached and at least three of them can end in no. A route existing at the level of regulation is not the same as a route being open to any individual who asks for it.
Route two: a telehealth hormone or longevity clinic
This is route one with the hardest step, finding a willing prescriber, solved as a product. The clinic supplies the consultation, orders the laboratory work, writes the prescription if it agrees, and arranges the fill.
The friction is lower and the elapsed time is shorter, and what replaces it is a commercial relationship: fees, a recurring programme, and a pharmacy selected by the clinic rather than by you.
The caution worth stating plainly is not that these clinics are illegitimate. It is that the proposition they sell is adult vitality, sleep and body composition, and that is the use with no literature behind it. The three papers with sermorelin in the title are a 2006 review in Clinical Interventions in Aging on adult-onset growth hormone insufficiency, a 1999 BioDrugs review on diagnosis and treatment in children with idiopathic growth hormone deficiency, and a 2021 paper in Annals of Translational Medicine on recurrent glioma. That is the whole title-level literature.
Route three: a domestic research supplier
Almost no friction. A listing, a card, an address, and a lyophilised vial arrives with a research use designation.
What it asks of you is everything the other routes handled. There is no prescriber, no pharmacist, no dispensing record and nobody who can be asked a question about suitability. The certificate is the only instrument in the transaction, which makes its scope the entire quality argument. On lot 38-01260229 that scope was purity at 99.79 percent by HPLC-UV-MS and a measured 11.31 mg against a 10 mg label, with no endotoxin test and no sterility test on the document. Our reading a listing guide covers what to check and in what order.
Route four: an overseas listing
Lower price, higher variance, and a customs step you neither see nor control. It also tends to remove the batch-specific certificate, which removes the only check the research route offers.
The saving is real. It is a saving purchased by giving up the document and the recourse, and those are the two things route three still had.
The step nobody counts: deciding what you are actually asking for
Before any route starts there is a decision most people skip, and skipping it is the most common way to waste the slowest route.
Sermorelin is a secretagogue. It is a synthetic twenty nine amino acid peptide identical to the active N-terminal fragment of growth hormone-releasing hormone, and it binds the GHRH receptor on the anterior pituitary and prompts release of the body's own growth hormone. It is not growth hormone. That is the honest answer to the question most people are really asking when they start looking, and it changes what a consultation is about.
The compounds sold beside it are not interchangeable either. Tesamorelin is a stabilised GHRH analog and is currently approved as Egrifta. Ipamorelin and MK-677 act at the ghrelin receptor rather than the GHRH receptor, and both carry Category 2 listings that sermorelin does not. Four different molecules, four different regulatory positions, routinely sold as one category. Our page on buying sermorelin as a peptide works through how to tell them apart on a certificate.
Arriving at any of these routes without that distinction settled means asking a prescriber, or a checkout, for something you have not defined.
What a prescriber is being asked to do
It is worth understanding the request from the other side of the desk, because it explains why route one is slow in a way that no amount of preparation removes.
There is no current US label for sermorelin. The prescriber is not selecting an approved product with an approved indication and an approved population. They are exercising individual clinical judgement about a preparation that a pharmacy will make for one named patient, and they carry that judgement personally.
That makes the specificity of the ask matter. A documented clinical question, with the laboratory work a prescriber would want to see attached to it, is a different conversation from a general wish to feel better. It is also why the assessment and the bloodwork are not administrative hurdles bolted onto the route. They are the route.
The pharmacy is a second, independent decision point. A 503A pharmacy is permitted to compound with this substance; it is not obliged to, and it may decline for reasons that have nothing to do with you.
The four routes by friction
| Route | Gatekeepers in the sequence | Where it can end in no | What you are left carrying |
|---|---|---|---|
| Prescriber and 503A pharmacy | Prescriber, laboratory results, pharmacy | At the consultation, after the labs, or at the pharmacy | Least. A pharmacist of record and a dispensing record exist |
| Telehealth clinic | The clinic's own clinician | At their assessment | Fees and a programme, with oversight included |
| Domestic research supplier | None | Nowhere | Everything. Identity, scope and suitability are all yours |
| Overseas listing | Customs, unpredictably | At the border, with no explanation | Everything, minus the certificate and the recourse |
The columns move together. Every gatekeeper removed is a delay removed and a check removed, and there is no arrangement in which you get one without the other.
Where readers actually land
Most people reading a page like this will take route three. Pretending otherwise would make the rest of this useless, so it is worth being direct about what that choice obliges.
It means the certificate check is not optional, because it is the only check left. It means the lot number on the vial has to match the document, and that testing scope is read as a property of that batch rather than of the brand. FDA's stated concern for the peptides it did place in Category 2 is the "risk for immunogenicity ... due to the potential for aggregation and peptide-related impurities", and a purity figure by HPLC is a partial answer to that at best.
It also means holding two things at once. Sermorelin is a real compound with a real regulatory history, correctly identified on the certificate as GHRH(1-29) amide against PubChem CID 16132413, formula C149H246N44O42S, molecular weight 3357.9 g/mol. And the adult use the market is built around returns zero papers on PubMed for sermorelin and anti-aging, with no registered studies naming it on ClinicalTrials.gov.
There is one more thing route three does not remove, and it is easy to miss because it happens after the interesting part is over. Nobody is monitoring anything. The prescription route builds review into the arrangement by design, since the prescriber who wrote it expects to see you again and the laboratory work is the reason for the appointment. The research route ends at delivery. Whatever happens next has no scheduled point at which a person looks at it, and the absence of that point is not something the certificate, the price or the shipping speed can compensate for.
If the prescription route is the one you want, it is set out step by step on our sermorelin prescription page, including what a prescriber is likely to ask for. If you are weighing the same trade for a different compound, our how to get retatrutide guide runs the identical ranking, and reaches a very different conclusion about route one.